CompletedNot Applicable

Trial to Evaluate the Efficacy and Safety of Substrate Ablation of Monomorphic Ventricular Tachycardia

Spain180 participantsStarted 2010-07

Plain-language summary

To compare the efficacy and safety of substrate-based radiofrequency catheter ablation vs. antiarrhythmic drug therapy in patients with ischemic cardiomyopathy and scar-related sustained monomorphic ventricular tachycardia.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Ischemic cardiomyopathy, with ischemic myocardial scar * Sustained monomorphic ventricular tachycardia * Age \> 18 years * Prior ICD implantation Exclusion Criteria: * VT storm * NYHA functional class IV * Additional indication for antiarrhythmic drug therapy * Contraindication for both study drugs (amiodarone and sotalol). * Uncontrolled myocardial ischemia. * LV thrombus. * Non-ischemic VT substrate. * Contraindications for anticoagulation. * Prior substrate ablation in the previous 6 months * Cr \> 2.5 mg/dL * Mitral AND aortic mechanical valvular prosthesis

What they're measuring

Occurrence of death from cardiovascular causes.

Timeframe: 2 years

Occurrence of appropriate shocks for VT/VF

Timeframe: 2 years

Occurrence of hospitalization for heart failure

Timeframe: 2 years

Occurrence of severe complication of the ablation procedure.

Timeframe: 2 years

Occurrence of interruption of antiarrhythmic drug therapy due to severe side effects

Timeframe: 2 years

Trial details

NCT IDNCT03734562

SponsorHospital General Universitario Gregorio Marañon

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2017-09-29

View on ClinicalTrials.gov More Monomorphic Ventricular Tachycardia trials